These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11759229)

  • 21. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

  • 22. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS
    Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of rheumatoid arthritis.
    Emery P
    BMJ; 2006 Jan; 332(7534):152-5. PubMed ID: 16424492
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

  • 26. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 27. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
    Smolen JS; Weinblatt ME
    Ann Rheum Dis; 2008 Nov; 67(11):1497-8. PubMed ID: 18854512
    [No Abstract]   [Full Text] [Related]  

  • 28. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
    Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
    [No Abstract]   [Full Text] [Related]  

  • 29. New drugs for rheumatoid arthritis.
    Kalil AC
    N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15609422
    [No Abstract]   [Full Text] [Related]  

  • 30. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
    Deighton C; Hyrich K; Ding T; Ledingham J; Lunt M; Luqmani R; Kiely P; Bukhari M; Abernethy R; Ostor A; Bosworth A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2010 Jun; 49(6):1197-9. PubMed ID: 20308121
    [No Abstract]   [Full Text] [Related]  

  • 31. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 32. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent therapeutic advances in the treatment of rheumatoid arthritis.
    Jonas BL
    N C Med J; 2007; 68(6):425-6. PubMed ID: 18236860
    [No Abstract]   [Full Text] [Related]  

  • 34. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 35. Biologics in rheumatoid arthritis--recommendations for Swiss practice.
    Dudler J; Möller B; Michel BA; Villiger PM
    Swiss Med Wkly; 2011; 141():w13189. PubMed ID: 21557111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination cytokine blockade: the way forward in therapy for rheumatoid arthritis?
    Taylor PC; Williams RO
    Arthritis Rheumatol; 2015 Jan; 67(1):14-6. PubMed ID: 25302944
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
    Payet S; Pereira B; Soubrier M; Mathieu S
    Semin Arthritis Rheum; 2012 Feb; 41(4):e4-5; author reply e6. PubMed ID: 22154222
    [No Abstract]   [Full Text] [Related]  

  • 38. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of the determination of the CD20 antigen through quantitative flow cytometry in complex cases of rheumatoid arthritis treated with anti-TNF-alpha.
    Hobi A; Bihl T; Fellay B; Waldburger M
    Rheumatol Int; 2006 Oct; 26(12):1161-2. PubMed ID: 16799779
    [No Abstract]   [Full Text] [Related]  

  • 40. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
    Smolen JS; Aletaha D
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.